ASCO: J&J, AbbVie go back to Imbruvica's roots in lymphoma. Will lack of survival win matter?

Back in 2013, AbbVie and Johnson & Johnson’s Imbruvica got its very first FDA go-ahead, which was for previously treated mantle cell lymphoma (MCL). Now, the company is trumpeting a trial win in newly diagnosed patients despite not showing a life-extension advantage.